Wave life sciences announces positive results from phase 1b/2a select-hd trial with first clinical demonstration of allele-selective mutant huntingtin lowering in huntington's disease

Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in csf mutant huntingtin (mhtt) protein compared to placebo, preservation of wild-type huntingtin (wthtt) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort
WVE Ratings Summary
WVE Quant Ranking